Insider Selling: Array BioPharma Inc. (ARRY) COO Sells 282,874 Shares of Stock

Array BioPharma Inc. (NASDAQ:ARRY) COO Andrew R. Robbins sold 282,874 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $10.72, for a total value of $3,032,409.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Array BioPharma Inc. (NASDAQ ARRY) traded down $0.24 on Friday, reaching $13.71. The company had a trading volume of 2,979,469 shares, compared to its average volume of 3,918,456. Array BioPharma Inc. has a 12-month low of $6.73 and a 12-month high of $14.40. The company has a current ratio of 5.43, a quick ratio of 5.43 and a debt-to-equity ratio of 0.54. The firm has a market cap of $2,700.00, a PE ratio of -18.53 and a beta of 1.91.

Array BioPharma (NASDAQ:ARRY) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting the consensus estimate of ($0.22). Array BioPharma had a negative return on equity of 158.70% and a negative net margin of 89.30%. The firm had revenue of $29.75 million for the quarter, compared to analysts’ expectations of $33.74 million. During the same period last year, the firm earned ($0.20) EPS. The firm’s revenue was down 24.2% compared to the same quarter last year. equities analysts predict that Array BioPharma Inc. will post -0.99 EPS for the current fiscal year.

A number of analysts have recently weighed in on ARRY shares. Stifel Nicolaus reiterated a “buy” rating on shares of Array BioPharma in a research report on Wednesday, November 1st. BidaskClub cut Array BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 2nd. Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price target (up from $14.00) on shares of Array BioPharma in a research report on Wednesday, September 20th. Jefferies Group increased their price target on Array BioPharma to $13.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research cut Array BioPharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. Array BioPharma has an average rating of “Buy” and a consensus target price of $14.10.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its position in Array BioPharma by 8.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 12,737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 972 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Array BioPharma by 7.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 15,148 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,012 shares during the period. Amalgamated Bank boosted its stake in shares of Array BioPharma by 5.6% during the 2nd quarter. Amalgamated Bank now owns 22,141 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 1,174 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Array BioPharma by 9.1% during the 2nd quarter. Prudential Financial Inc. now owns 18,957 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 1,580 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Array BioPharma by 3.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,865 shares of the biopharmaceutical company’s stock worth $1,112,000 after acquiring an additional 4,287 shares in the last quarter. Hedge funds and other institutional investors own 98.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Array BioPharma Inc. (ARRY) COO Sells 282,874 Shares of Stock” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/01/13/andrew-r-robbins-sells-282874-shares-of-array-biopharma-inc-arry-stock.html.

About Array BioPharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Receive News & Ratings for Array BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply